双特异性抗体的临床应用进展
摘要
天然的单体抗体分子具有两条相同的配基识别臂,若将其中配基识别臂替换,使其能够结合另一种配基,即成为双特异性抗体(bispecificantibody,BsAb)。早在19世纪末BsAb就被描述为专门针对微生物,而保留正常宿主细胞能力的一种化学物质。其特点是在同一抗体分子的两个抗原结合臂,可同时结合两个不同的抗原,一个与靶抗原结合;另一个与免疫效应细胞上的标志抗原结合,能在靶细胞和功能分子(细胞)之间架起桥梁,激发具有导向性的免疫反应。本文仅就BsAb临床上的应用进行简要综述如下。
出处
《放射免疫学杂志》
CAS
2013年第5期587-589,共3页
Journal of Radioimmanology
参考文献19
-
1Koelemij R, Kuppen PJ, Van de velde C J, et al. Bispecific antibody in cancer therapy,from the laboratory to the clinic [J]. J Immunother, 1999,22(6) :514-524.
-
2Breman M,Davison PF,Paulus H. Preparation of bispecific antibod- ies by chemical recombination of monoclonal immunoglobuling, fragments [ J]. Science, 1985,229:81--83.
-
3De Gast GC, Haagen IA, Van Houten AH, et al. CD8 T cell activa- tion after intravenous administration of CD3 x CD19 bispecific antibody in patients with non-Hodgkin lymphoma [ J ]. Cancer Immunol Immunother, 1995,40(6) :390-396.
-
4Chan JK, Hamilton CA, Cheung MK, et al. Enhanced killing of pri- mary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study [ J ]. Clin Cancer Res, 2006, 12(6) :1859-1867.
-
5Cioffi M,Dorado J,Baeuerle PA,et al. EpCAM/CD3 Bispecific T- cell engaging antibody MT110 eliminates primary human pancreastic canc- er stem cells [J]. Clin Cancer Res,2012,18(2) :465-474.
-
6Stanglmaier M, Faltin M, Ruf P, et al. Bizo ( BTAo5 ), a novel tri- functional bispecific antibody( anfi-CD20 x anti-CD3 ), mediates efficient killing of B-cell lymphoma cells even with very low CD20 expression levels [J]. Int J Cancer, 2008,123(5) :1181-1189.
-
7Azria D, Dorvillius M, Gourgan S, et al. Enhancement of radiation therapy by tumor necrosis factor alpha in human colon cancer using a bis- pecific antibody [ J ]. Int J Radiat Oneol Bid Phys, 2003, 55 ( 5 ) : 1363-1373.
-
8Thakur A,Sorenson C ,Nokina C, et al. Activated T cells from um- bilical cord blood armed with anfi-CD3 x anfi-CD20 bispecific antibody mediate specific cytotox/city against CD20 + targets with minimal allogene- ic reactivity: a strategy for providing antitumor effects after cord blood transplants[ J]. Transfusion, 2012,52( 1 ) :63-75.
-
9Otz T, Grosse-Hovest L, Hofmann M, et al. A bispecific single- chain antibody that mediates target cell-restricted, supra*agonistic CD28 stimulation and killing of lymphoma cells[ J]. Leulmia, 2009,23 ( 1 ) :71- 77.
-
10Tam SW,Demissie S, Thomas D, et al. A bispecific antibody a- u, ainstt human IgE and human fexmmma R ]I that inhibits antigen-inducedhistamine release by human mast cells and basophils [J]. Allergy, 2004, 59 (7) :772-780.
二级参考文献9
-
1Gelderman KA, Blok VT, Fleuren GJ, Gorter A. The inhibitory effect of CD46, CD55, and CD59 on complement activation after immunotherapeutic treatment of cervical carcinoma cells with monoclonal antibodies or bis-pecific monoclonal antibodies[J]. Lab Inves
-
2Xiong D, Xu Y, Liu H, Peng H, Shao X, Lai Z, Fan D, Yang M, Han J, Xie Y, Yang C, 2hu Z. Efficient inhibition of human B-cell lymphoma xen ografts with an anti-CD20 x anti-CD3 bispecific diabody[J].Cancer Lett, 2002,177(1) :29.
-
3Micheel B, JantscheffP, Bottger V, et al. The production and radio-immunossay application of monoclonal antibodies to fluorescein isothiocyanate (FITC)[J]. J Immunol Methods, 1988,111:89.
-
4Gani M et al. A simple method of labeling mouse Thy-1 antibodies with FTTC[J]. J Immunol Methods, 1980,34:133.
-
5Karawajew L, et al. Production and ELISA application of bispecific monoclonal antibodies against fluorescein isothio cyanate(FITC) and horseradish peroxidase(HRP)[J]. J Immunol Method, 1988,111:95.
-
6Platt .JL, Michael AF. Retardation of fading and enhancement of intensity of immunofluorescence by phenylendiamine[J]. J Histochemistry Cytochemistry, 1983,31:840.
-
7Weiner LM, Adams GP. New approaches to an Oncogene[J]. Cancer Res, 2000,19(53):6144.
-
8钟立业,陈运贤,林伟.双特异性抗体治疗恶性肿瘤[J].肿瘤研究与临床,2001,13(1):67-69. 被引量:2
-
9张辛燕,李小平.双特异性抗体治疗恶性肿瘤的研究进展[J].国外医学(肿瘤学分册),2002,29(3):178-181. 被引量:3
共引文献3
-
1马雄华,韩颖超,李世普.生物标记用发光材料研究现状[J].河南化工,2006,23(5):1-4. 被引量:2
-
2马雄华,韩颖超,李世普.生物标记用发光材料研究现状[J].化工中间体,2006,2(8):4-7. 被引量:2
-
3曾丹林,陈诗渊,张崎,刘胜兰.纤维素制备微球材料的研究进展[J].材料导报,2015,29(17):68-72. 被引量:5
-
1何晓婷,李怀芳.人脐血间充质干细胞分离培养的研究进展[J].同济大学学报(医学版),2011,32(1):120-124. 被引量:2
-
2刘艳君,罗冰,赵文忠,朱平,富宁.人TLR-2胞外肽段的分段表达及其活性鉴定[J].现代免疫学,2006,26(4):269-273. 被引量:1
-
3何凌宇,项军,梅健,王岩,王磊,刘成,薛松.羊水干细胞对梗死心肌的修复作用[J].实用心脑肺血管病杂志,2013,21(7):11-13.
-
4凌生林,付勇,廖斌.B族I型清道夫受体的研究进展[J].泸州医学院学报,2008,31(5):580-582. 被引量:1
-
5孙琳,冯惊涛,易光辉.B类Ⅰ型清道夫受体与胆固醇的双向转运[J].中国动脉硬化杂志,2007,15(1):67-70. 被引量:2
-
6徐舒,吕志平.干细胞肝移植实验研究进展[J].中华肝胆外科杂志,2005,11(12):860-861.
-
7宋振顺,顾克菊.胰腺干细胞研究进展[J].武警医学,2003,14(7):389-392. 被引量:1
-
8王宁利.加强学科交叉促进我国神经眼科学的发展[J].中华眼科杂志,2010,46(12):1057-1058. 被引量:12
-
9科研方案都包括哪些内容?[J].护士进修杂志,2012,27(3):243-243.
-
10陈孝文,黄柳涛,刘华锋.肾脏病组织生物样本库的现状和发展趋势[J].中国中西医结合肾病杂志,2014,15(4):283-286.